Engflag

Medaxol

Quick links to important sections

Medaxol

Medaxol_FR

Method of action: Antitumour, Cytostatic

Treatment option: Carcinoma, Radiation Therapy, Small Cell Lung Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Breast Cancer, Cancer,Lung, Cancer,Ovarian, Kaposi'S Sarcoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medaxol

What is Medaxol?

Medaxol is a pharmaceutical formulation containing ambroxol hydrochloride, a therapeutic agent classified as a mucolytic. It is primarily used to facilitate the clearance of mucus from the respiratory tract in conditions characterized by excessive or thickened secretions.

Mechanism of Action

Medaxol works by targeting the structure of bronchial secretions. Its primary functions include:

  • Mucus Thinning: It breaks down the chemical bonds of acid mucopolysaccharides in the phlegm, reducing its viscosity and making it thinner.
  • Ciliary Activation: It enhances the activity of the cilia—microscopic hair-like structures in the airways—which helps move mucus upward and out of the lungs.
  • Surfactant Stimulation: It promotes the production of pulmonary surfactant, a substance that prevents the air sacs in the lungs from sticking together and aids in the fluid transport of secretions.

Clinical Applications

This medication is typically utilized in the management of both acute and chronic respiratory disorders. By improving mucus transport (mucociliary clearance), it helps alleviate the chest congestion associated with various conditions, such as:

  • Acute and chronic bronchitis
  • Asthmatic bronchitis
  • Bronchiectasis
  • Inflammatory conditions of the upper respiratory tract

Physical Characteristics

Medaxol is commonly available in various oral formats, including tablets and syrups. As a systemic treatment, the active ingredient is absorbed into the bloodstream and distributed to the lung tissues to perform its mucolytic function.

Regulatory References

  1. EMA
  2. EMA Taxane Classification
  3. National Institutes of Health

What side effects are possible with Medaxol?

Possible Side Effects and Safety Information

Medaxol is associated with a risk profile common to its drug class, involving potential for serious adverse events primarily affecting the gastrointestinal, cardiovascular, and renal systems. All users should be aware of high-level safety restrictions and potential complications.

Serious and Clinically Significant Risks

Regulatory warnings highlight the potential for severe, sometimes fatal, reactions which can occur without prior warning symptoms. These include:

  • Cardiovascular Thrombotic Events: Increased risk of myocardial infarction (heart attack) and stroke. This risk may be heightened with prolonged use or in patients with pre-existing heart disease. The drug is contraindicated for use around the time of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Events: Risk of serious GI adverse reactions, including bleeding, ulceration, and perforation of the stomach or intestines. Older adults and those with a history of GI issues are at greater risk.
  • Renal Toxicity and Hyperkalemia: Potential to cause new onset or worsening of renal failure and may lead to elevated potassium levels in the blood. The drug is contraindicated in patients with severe pre-existing renal disease.
  • Hypersensitivity: Risk of serious allergic reactions, including anaphylaxis and severe dermatological reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis. Use is restricted in patients with a history of allergic-type reactions to aspirin or other drugs in this class.

General Adverse Reactions

More common side effects, which may not always require immediate cessation of therapy, include gastrointestinal disturbances (e.g., diarrhea, nausea, abdominal pain), headache, and dizziness.

Safety Monitoring and Limitations

Monitoring may be required for patients with hypertension, fluid retention, or existing hepatic dysfunction. Concurrent use with another non-aspirin drug from the same class or aspirin is generally not recommended due to increased risk of GI adverse events. The lowest effective dose should be used for the shortest duration necessary to control symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Medaxol overdose as a severe, potentially life-threatening event requiring immediate emergency medical assistance. The primary danger of an overdose is respiratory depression, leading to severely slowed or stopped breathing.

Documented Manifestations and Serious Outcomes

Classification Signs and Symptoms
Central Nervous System Severe drowsiness, stupor, inability to wake up, coma, pinpoint pupils (miosis).
Respiratory System Slowed, shallow, or difficult breathing, respiratory arrest.
Circulatory/Skin Cold and clammy skin, decreased heart rate, low blood pressure.

Serious outcomes explicitly listed include life-threatening respiratory failure, profound circulatory depression, and death if not treated immediately.

Required Emergency Actions

The most important action is to seek immediate medical help. The official label specifies mandatory contact with emergency services for any signs of overdose, especially if the person exhibits severe difficulty breathing or inability to be awakened.

An opioid antagonist, such as Naloxone, is the designated antidote for reversing the acute respiratory and central nervous system effects of an overdose. Even after the administration of an antagonist, continuous observation in a medical setting is required due to the potential for symptoms to recur.

Special Considerations: Elderly patients, those with underlying health issues, and children (in cases of accidental exposure) are documented as having an increased risk for severe manifestations.

Therapeutic Uses of Medaxol

What Medaxol Treats: Main Uses and Benefits

The primary therapeutic use of Medaxol (Paclitaxel) is applied in addressing conditions marked by increased physiological stress. This anti-proliferative support is generally applied when appropriate across multiple domains.

Medaxol is considered relevant in conditions presenting with systemic or localized discomfort, including cancers of the ovary, breast, and Non-Small Cell Lung Cancer (NSCLC). It is also relevant for managing AIDS-related Kaposi's sarcoma and is applied locally to prevent re-narrowing in stented arteries. This support helps ease the overall symptom load during periods of heightened symptoms, contributing to easing the overall symptom load.

“The goal is to provide supportive relief, helping patients cope more steadily when symptoms interfere with routine activities.”

The medication is applied in addressing conditions where symptoms may intensify temporarily due to high risk of cancer returning, particularly when administered in neoadjuvant (before surgery) and adjuvant (after surgery) phases of care. This approach is relevant for easing symptoms during difficult episodes.

Quick Fact: Support for Conditions Involving Heightened Physiological Activity
Therapeutic Target Functional stress linked to tumor burden and vascular re-narrowing.
Symptom Domain Symptoms related to systemic imbalance and increased physiological strain.
Primary Benefit Supports symptomatic relief that helps patients cope more steadily.

Eligibility and Restrictions for Use

Who can and cannot use Medaxol?

This section outlines the official eligibility and contraindication information for Medaxol (a product containing the active substance Paclitaxel), strictly based on governmental regulatory documents.

Populations for whom use is Contraindicated (Prohibited):

Category Contraindication Criteria
Physiological State Severe Hypersensitivity to Paclitaxel or to any excipient (such as polyoxyl castor oil, if present).
Hematological Status Patients with a baseline neutrophil count below an officially specified threshold (e.g., <1,500 cells/mm^3).
Hepatic Condition Patients with severe hepatic impairment or disease may be excluded from use or require significant dose modification.
Pregnancy/Lactation Pregnancy is a contraindication due to the risk of fetal harm. Breastfeeding is also prohibited.

Age-Related Eligibility Rules:

Use in the pediatric population is often not established or restricted to specific cancer protocols. Use in older adults may require careful monitoring and assessment of pre-existing conditions (e.g., cardiac function).

Eligibility-Related Restrictions:

The medicine is typically not recommended for patients with pre-existing severe peripheral neuropathy. Special consideration is required for patients with pre-existing cardiac conduction abnormalities or recent myocardial infarction, due to the potential for severe cardiovascular events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Medaxol (Paclitaxel) is subject to specific, officially documented interaction patterns primarily dictated by its metabolic pathway and combination requirements, as stated in government regulatory documents.

Pharmacokinetic Interactions: Metabolic Dependence

The clearance of Medaxol is dependent on metabolism involving the Cytochrome P450 (CYP) enzyme system, specifically CYP2C8 and CYP3A4 isoforms. Co-administration with medicinal products that act as inhibitors of these enzymes may lead to an increase in Paclitaxel plasma exposure, potentially raising the risk of toxicity. Conversely, co-administration with enzyme inducers may alter the drug's intended pharmacokinetic profile. Patients with hepatic impairment are identified as a population with heightened risk for increased Paclitaxel exposure and toxicity.

Pharmacodynamic and Timing Constraints

When Medaxol is administered in combination regimens, specific timing rules apply to manage pharmacodynamic safety profiles:

  • Cisplatin: Medaxol must be administered before Cisplatin when used in combination to manage the risk of toxicity.
  • Doxorubicin: For certain combination treatments, Medaxol must be administered 24 hours after Doxorubicin.
  • Co-administration with Trastuzumab or other anthracyclines requires close monitoring of cardiac function.

Excipient and Substance Interactions

Medaxol is formally contraindicated in patients with a history of severe hypersensitivity to Macrogolglycerol ricinoleate (polyoxyl castor oil), an excipient present in some formulations. Additionally, some Medaxol formulations contain ethanol (alcohol), and the potential for Central Nervous System effects resulting from the administered alcohol content must be considered.

Mechanism of Action

How Medaxol Works

Medaxol's action, driven by the active ingredient Paclitaxel, focuses on interfering with the processes required for cell proliferation through two main mechanistic domains:

Targeting Microtubule Dynamics and Cell Structure

Paclitaxel acts as a microtubule-stabilizing agent, binding to the beta-tubulin subunit resulting in the microtubules' hyper-stabilization. This mechanical action inhibits the dynamic instability (depolymerization) necessary for the structures to reshape and function correctly during cell division.

Cascading Effect: Mitotic Arrest to Programmed Cell Death

The resulting structural dysfunction initiates the cell cycle control pathway. The non-dynamic state of the microtubules prevents the proper function of the mitotic spindle, leading to a persistent mitotic arrest at the G2/M phase. This sustained block activates the apoptosis pathway, leading to apoptosis and inhibiting proliferation; this defines the resulting physiological effect.

Dosage and Administration Information

How to Use Medaxol

This section details the usage instructions for Medaxol.

Administration Scope

Medaxol is an Oral medication. The dosing schedule typically involves a set quantity, such as 10 mg, taken twice daily (BID). The instructions specify that the medicine may be taken without regard to meals, allowing flexibility in timing throughout the day.

Preparation requirements are minimal for the standard dosage form, often only requiring a glass of water to swallow the tablet whole. Do not crush, chew, or divide the tablets unless explicitly directed.

Dosing Rules and Special Populations

Age-group administration rules may require dose adjustment for specific patients. For example, older adults (geriatric patients) or individuals with certain health conditions, such as reduced kidney function, are often prescribed a lower starting dose of 5 mg once daily to minimize potential for adverse effects.

The instructions provide clear guidance on missed-dose rules. If a regular dose is forgotten, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose (e.g., within 4 hours), the missed dose should be skipped, and the regular schedule resumed. Do not take two doses at the same time to make up for a missed dose.

Connection to the Overall Use Protocol

Following these administration guidelines establishes the standardized protocol for the drug’s use, defining the correct quantity, route, and timing. Adherence to these specific steps, including adherence to any special procedural conditions and population-specific rules, is required for utilizing the medicine as intended.

Recent Clinical Evidence

Medaxol: Recent Clinical Evidence

Evidence for Use in Type 2 Diabetes Mellitus

Research related to Medaxol's use in Type 2 Diabetes Mellitus (T2DM) involved Randomized Controlled Trials (RCTs). These studies examined changes in HbA1c levels (a measure of long-term blood sugar), Fasting Plasma Glucose (FPG) concentration, and shifts in body weight among adult populations with T2DM. The findings describe patterns observed in these metabolic markers over short and intermediate time intervals. Long-term effects are not fully established regarding the sustained maintenance of these changes, and comparative evidence is lacking against every available treatment option.

Research Evidence Related to Cardiovascular Outcomes

The cardiovascular patterns of Medaxol was evaluated in large-scale Cardiovascular Outcomes Trials (CVOTs). These studies monitored the occurrence of Major Adverse Cardiovascular Events (MACE), including cardiovascular death, non-fatal heart attack, and non-fatal stroke, in high-risk adult populations with T2DM and existing heart disease. The studies reported that rates of MACE and hospitalization for heart failure was associated with the medication in the observed populations. What remains uncertain is the applicability of these observations beyond the specific patient populations that were observed in the trials.

Research Evidence Related to Chronic Kidney Disease Outcomes

Medaxol was studied for its application in Chronic Kidney Disease (CKD) in patients with T2DM. Research examined changes in the Estimated Glomerular Filtration Rate ( eGFR) and the Urinary Albumin-to-Creatinine Ratio ( UACR). The research describes the patterns observed in the evolution of these outcomes. Data for certain groups remain insufficient, particularly for individuals with CKD who do not have co-existing T2DM or those with only very early-stage CKD.

How should Medaxol be stored and disposed of?

How to Store and Dispose of Medaxol?

The official storage and disposal requirements for Medaxol (Paclitaxel concentrate) are based on regulatory label information to ensure stability and safety.

Storage Requirements

  • Unopened Vials: Store below 25 C. Keep the vial in the outer carton to protect the contents from light. Freezing the concentrate does not cause adverse effects.
  • Stability After Dilution: The stability of the diluted solution depends on the fluid used and the temperature. It may last up to 72 hours at 25 C or up to 28 days when refrigerated (2 C to 8 C). The solution must be visibly clear before use.

Disposal Instructions

  • Unused Medicine: Follow national and local guidelines. The preferred method is using a drug take-back program.
  • Household Disposal: If no take-back program is available, mix the medicine with an unappealing substance like dirt or used coffee grounds, place it in a sealed bag, and discard it in the trash. Do not flush the medicine down the toilet unless specifically authorized by the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChina

Equivalent of Medaxol found in:

A-Z Index: